南方医科大学学报

南方医科大学学报 ›› 2013, Vol. 33 ›› Issue (04): 550-.

• • 上一篇    下一篇

肾癌患者外周血中CD33+HLA-DR-髓源抑制性细胞的表达及其临床意义

奉松青，刘春晓，郑少波，黄鹏，陈玢屾，郭凯   

  • 出版日期:2013-04-20 发布日期:2013-04-20

  • Online:2013-04-20 Published:2013-04-20

PDF

1098

摘要： 目的探讨肾癌患者外周血中CD33+HLA-DR-髓源抑制性细胞（MDSCs）的表达及其与肿瘤分期和病理类型的相关性。
方法采用流式细胞术检测肾癌患者（44例）和健康志愿者外周血中CD33+HLA-DR- MDSCs水平，并分析其与肿瘤进展及肿瘤
病理类型的相关性。结果肾癌患者外周血中CD33+HLA-DR- MDSCs的表达显著高于健康对照组［（1.91±0.66）% vs（0.62±
0.22）%，P<0.001］；根据肿瘤分期划分，晚期（Ⅳ期）肾癌外周血CD33+ HLA-DR- MDSCs表达明显增高：Ⅰ+Ⅱ期∶Ⅲ期［（1.46±
0.44）%∶（2.04±0.35）%，P<0.01］；Ⅲ期：Ⅳ期［（2.04±0.35）%∶（2.50±0.64）%，P<0.05］；肿瘤患者外周血中CD33+ HLA-DRMDSCs
的表达与患者性别和年龄无明显相关性（P>0.05）。结论肾癌患者外周血中CD33+ HLA-DR- MDSCs表达与肿瘤分
期、分型相关，对肾癌患者的预后及肿瘤免疫方面的研究有显著意义。

Abstract: Objective To investigate the expression of CD33 + HLA-DR- myeloid-derived suppressor cells (MDSCs) in the
peripheral blood of patients with renal carcinoma and its correlation with the clinicopathological features of renal cancer.
Methods Forty-four patients with renal carcinoma treated in our hospital between June, 2011 and October, 2012 and 18 healthy
volunteers were enrolled in this study. Flow cytometry was performed to detect CD33 + HLA-DR- MDSCs in the peripheral
blood, and its correlation with the clinicopathological features of the patients were analyzed. Results The positivity rate of
CD33+ HLA-DR- MDSCs in the peripheral blood was significantly higher in the cancer patients than in the healthy controls
[(1.91 ± 0.66)% vs (0.62 ± 0.22)%, P<0.001]. The expression levels of CD33 + HLA-DR- MDSCs in patients with renal carcinoma
showed significant differences between stage I+II [(1.46±0.44)%] and stage III [(2.04±0.35)%] patients (P<0.01) and between
stage III and stage IV patients [(2.50±0.64)%] (P<0.05), but did not differ significantly in respect of age or gender. Conclusion
CD33 + HLA-DR- MDSCs expression in the peripheral blood is associated with tumor stage and differentiation in renal
carcinoma and may play an important role in predicting the prognosis and tumor immunology of renal carcinoma.